What is the MAB?
MaB is a market oriented towards small-cap companies looking to expand, with tailor-made regulation designed specifically for them and costs and processes adapted to their characteristics, allowing them to benefit from the advantages of the market: financing, visibility, liquidity, valuation.....
To ensure transparency in the market it is necessary for each company to have a Registered Advisor, who assists the company in the whole process, from market entry to day-to-day trading.
Why is the MAB important for SMEs?
Facilitates access to finance.
They gain access to new investors, other than venture capital or business angels.
It helps to grow faster, via mergers and acquisitions. acquisitions.
It is a letter of introduction to your internationalisation process.
Changing its corporate culture: more transparent and more professional.
Alternative for continuity in family businesses, by broadening their shareholder base and allowing the departure of founding partners. It offers shareholders liquidity by allowing their shares to be converted into cash. It does not involve losing control of the company.
It allows the value of the company to be determined, as the market fixes the price of the shares, incorporating business expectations into the price.
Companies listed on the MAB
There are currently 33 growing companies listed on the MAB. In addition to companies, SOCIMIS, SICAVS, venture capital companies and hedge funds are also listed on the MAB.
Focusing on growth companies, the sector with the largest presence on the MAB is biotechnology with a total of 7 companies, followed by software and engineering with 5 and 4 companies respectively.
"It is difficult for venture capital to invest in biotechnology in Spain, because venture capital invests in short terms, it wants to exit after four or five years, while the maturity of biotech projects is much longer. In addition, the valuation logic of a biotech is different because of the risk associated with the development of its product portfolio. That is why the MAB gives a light to these biotech companies that want to grow", says Diego Gutierrez from Abra-Invest.
By capitalisation, the engineering and project development sector is gaining weight in the total market and together with the telecommunications sector represents 46% of the stock market capitalisation; with €529.8M.
Mab participation grows in the last half of 2015
During the last half of 2015 we have witnessed how several companies have decided to break the ice and go public on the MAB one year after the Gowex scandal came to light in July 2014.
"companies that are coming out are hiring top-tier firms. to comply with regulatory requirements and this is boosting investor confidence, so much so that according to AemabIn 15 years' time there will be 500 listed companies, whereas today there are 33," says Diego Gutiérrez of Abra-Invest.
In the last half of 2015, 7 SMEs were listed on the MAB, compared to only one in the first half of the year.
New companies on the MAB
If you want to know more about this market, please contact us. Abra-Invest has a team with extensive experience in alternative financing. Call us on + 34 946424142 or fill in the contact form.
Other posts that may interest you
Spanish biotech companies go public
ICO increases global Fondico to €1500M
October 2015: Funding for the biotech sector: InnoUp Farma and Oryzon Genomics and Mind The Byte
EN 
ES